The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EB | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors | |
5
|
L01EB11 |
| Active Ingredient |
|---|
|
Aumolertinib is an oral, third-generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It selectively and irreversibly inhibits both EGFR-sensitizing mutations (such as Exon 19 deletion and L858R) and the T790M resistance mutation. It is designed to be highly selective, minimizing impact on "wild-type" (normal) EGFR to reduce side effects. It is primarily used to treat non-small cell lung cancer (NSCLC) in patients with specific genetic mutations. |
| Document | Type | Information Source | |
|---|---|---|---|
| AUMSEQA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.